(Reuters) -Crystalys Therapeutics said on Tuesday it has emerged from stealth mode with a funding round of $205 million to help finance global late-stage trials of its lead drug as a treatment for ...

SAN DIEGO, March 5, 2025 /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 ...

Management of a patient allergic to allopurinol can be considered a therapeutic challenge. This article highlights the diversity of medications that can be used to manage hyperuricemia during this ...

Study Links GLP-1 Use to Higher Risk of Bone Conditions and Gout . The team analyzed electronic health records from people with diabetes and obesity who took GLP-1 drugs and compa ...

Natalie McCormick, PhD, of the Rheumatology and Allergy Clinical Epidemiology Research (RACER) Center within the Division of Rheumatology in the Mass General Brigham Department of Medicine, is the ...

A cheap gout drug may offer hope for thousands of patients with heart issues, promising new research has suggested. German and Swiss scientists tested colchicine on over 10,000 patients with a history ...

Gout inflammation may unfold in timed phases with distinct treatment windows. Read more about this precision model.

LIVERPOOL, ENGLAND — Optimizing how people experiencing a gout flare are managed in hospital and then followed-up afterwards can substantially increase the uptake of guideline-recommended ...

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price. Well intentioned, but costly and potentially problematic. That's how ...

GLP-1 medications such as Ozempic and Wegovy have transformed treatment for Type 2 diabetes and obesity, but new research suggests doctors may need to pay closer attention to bone health, especially ...